Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC
View More
Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?
View More
Taking a Critical Look at Healthcare Inequity Among Patients with Cancer: What Role Do Onco-Nurses Play?
View More
2023 ASCO Direct™ Highlights: Practice-Changing Data From the Leading Oncology Conference
View More
Neoadjuvant Immunotherapy in Melanoma: Where We Are, and Where We Aren’t
View More
2024 International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Comprehensive Patient Education and Symptom Awareness with GVHD
September 16th 2024Panelists discuss how nurse practitioners educate patients about chronic graft-versus-host disease (cGVHD) and its long-term effects, exploring various educational resources and materials such as brochures, apps, websites, and videos that are most effective in supporting patients and their caregivers.
Postsurgical Pembrolizumab/Chemotherapy Misses DFS Goal in Endometrial Cancer
While adjuvant pembrolizumab and chemotherapy with or without radiation did not boost DFS in the overall high-risk endometrial cancer population, but showed a trend toward improved DFS in one patient subgroup.
Consolidation Durvalumab Improves Survival in Small Cell Lung Cancer Subgroups
Consolidation durvalumab improved survival across subgroups of patients with limited-stage small cell lung cancer based on factors associated with prior prophylactic cranial irradiation and concurrent chemoradiotherapy use.